Shilpa Medicare launches dissolving oral thin films of Paracetamol
Shilpa's Paracetamol oral thin films are patent protected and are first of this kind in the world
Shilpa's Paracetamol oral thin films are patent protected and are first of this kind in the world
India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
The study was conducted in patients with mild to moderate COVID-19
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
NATCO Pharmaceuticals, Hyderabad; Alembic Pharmaceuticals, Vadodara; Gufic Biosciences Ltd., Gujarat; Emcure Pharmaceuticals, Pune; and Lyka, Gujarat are new manufacturers
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
Financial support is being provided as a grant from the Government of India
The company is working closely with its six manufacturing partners in India
Subscribe To Our Newsletter & Stay Updated